Retatrutide Box (10 x 10mg)

Retatrutide Box (10 x 10mg) — Bulk Triple GLP-1/GIP/Glucagon Receptor Research Peptide

Retatrutide, developed under the code name LY3437943 (also written LY-3437943), is a 39-amino-acid peptide engineered by Eli Lilly as a triple agonist of the GLP-1, GIP and glucagon receptors. It is commonly searched as retatrutide, the reta peptide, or simply reta. Its GIP-based backbone carries a fatty-acid side chain that binds reversibly to serum albumin, extending its half-life enough to support once-weekly dosing in research protocols.

This page is the Box of 10 x 10mg vials, our largest and best-value retatrutide format, built for labs running extended studies, several concurrent projects, or anyone who has already validated a 10mg dosing protocol and wants a full supply locked in at one price. Omega Peptides Australia's standard single-vial listing is the 10mg vial, which also carries 5mg, 20mg, 30mg and 60mg options if a single-vial size suits your protocol better.

Omega Peptides Australia supplies this box as ten individually sealed, high-purity (≥99% HPLC), COA-verified lyophilised vials. Orders placed before 12pm are dispatched the same day from within Australia, and the certificate for every batch is published in our COA library.

Key research areas

• Triple receptor agonism. Retatrutide is studied as the first clinical-stage peptide to activate all three major incretin/glucagon receptors at once: GLP-1R, GIP receptor (GIPR) and the glucagon receptor (GCGR). Researchers use it to compare single, dual and triple agonist mechanisms within the same experimental model.
• Body weight and energy expenditure. The added glucagon receptor activity is of particular research interest because glucagon signalling increases hepatic energy expenditure and lipolysis independently of appetite suppression, a mechanism not present in GLP-1-only or GLP-1/GIP dual agonists such as semaglutide or tirzepatide.
• Phase 3 clinical data (TRIUMPH program). Retatrutide has progressed through Eli Lilly's Phase 3 TRIUMPH program, including the TRIUMPH-1 and TRIUMPH-3 trials, which reached primary completion in April 2026. Published trial data has reported weight reductions in the order of 15 to 24 percent over 48 to 72 weeks, with some reports of up to roughly 28 percent at 80 weeks in extended dosing arms.
• Glycaemic control research. As with other incretin-based peptides, retatrutide is studied for its effect on insulin secretion, glucagon suppression in the fed state and glucose-dependent insulinotropic activity, with a comparatively low reported risk of hypoglycaemia in trial data.
• Long-duration, multi-batch consistency. A boxed set of ten identical 10mg vials is well suited to extended studies that need weeks of dosing from vials drawn from the same production run, or to labs running several parallel research models that each need their own dedicated vial.
• Tolerability profile. Gastrointestinal effects, including nausea and diarrhoea, are the most commonly reported adverse findings in trial data, consistent with the class-wide GI effects seen across incretin receptor agonists.

How retatrutide works

Retatrutide's peptide backbone is derived from GIP and engineered to also bind and activate the GLP-1 and glucagon receptors, making it a unimolecular triple agonist rather than a mixture of separate compounds. Activating GLP-1R and GIPR together enhances glucose-dependent insulin secretion and appetite suppression, the same mechanism exploited by dual agonists like tirzepatide. The addition of GCGR activity is what differentiates retatrutide: glucagon receptor signalling in the liver increases fatty acid oxidation and resting energy expenditure, an effect that in principle adds a metabolic-rate component on top of the appetite and insulin effects shared with dual and single agonists.

Like other long-acting incretin peptides, retatrutide carries a fatty diacid side chain attached via a linker to a lysine residue in its backbone. This lipidation allows the peptide to bind reversibly to circulating albumin, which slows renal clearance and extends its plasma half-life to a point that supports once-weekly administration in clinical dosing protocols. Ten individually sealed 10mg vials from the same batch give a multi-week protocol a consistent, traceable supply without needing to reorder mid-study.

Specifications

Box of 10: pricing and who it suits

The Box of 10 x 10mg vials is $1,099.99, about $109.99 per vial, compared with $159.99 for a single 10mg vial bought individually. That works out to roughly a 31 percent saving per vial when buying the full box. It's built for researchers who have already validated a 10mg dosing protocol and know they'll need a steady, traceable supply across an extended study, multiple research models, or several months of work, all drawn from vials packaged and dispatched together.

If you haven't settled on 10mg as your working dose yet, start with a 5mg or single 10mg vial first, or see our 20mg, 30mg and 60mg single-vial options if a different concentration suits your protocol better.

Quality and COA verification

Every batch of Retatrutide is independently tested by Janoshik Analytical. HPLC confirms purity of 99 percent or higher and mass spectrometry confirms that the measured mass matches the expected molecular weight of the 39-residue backbone, verifying identity as well as purity. A Certificate of Analysis is issued for every batch and published in our COA library, where the batch number on each vial can be matched to its report. All ten vials in this box are lyophilised and individually sealed under sterile conditions, and the full box is packed for domestic transit and shipped from Australian stock.

Frequently bought together

• Bacteriostatic Water (10mL) — $29.99, the standard diluent for reconstituting lyophilised peptides. Consider two or more given the number of vials in this box.
• Tirzepatide — a dual GLP-1/GIP receptor agonist, often studied alongside retatrutide as a comparator compound.
• Retatrutide Premium Kit — a fully bundled option including diluent and accessories.

Purchase other quantities

Retatrutide is available in several sizes across our store. If a box of ten 10mg vials is more than your protocol needs right now, see the links below for our single-vial listings.

• Retatrutide 10mg (single vial, and other sizes) — our main Retatrutide listing
• Retatrutide 5mg
• Retatrutide 20mg
• Retatrutide 30mg
• Retatrutide 60mg

Research guides

• Retatrutide research guide
• Best place to buy Retatrutide in Australia
• Retatrutide vs Tirzepatide
• Retatrutide Starter Kit
• Peptide reconstitution calculator

Frequently asked questions

What is reta?
Reta is the shorthand researchers use for retatrutide, a 39-amino-acid peptide developed by Eli Lilly under the code name LY3437943. Searches for reta, the reta peptide and retatrutide all refer to the same compound. Omega Peptides Australia supplies it as a lyophilised research peptide in single vials from 5mg to 60mg, and as this Box of 10 x 10mg vials, for laboratory use only.

What is retatrutide?
Retatrutide is a triple receptor agonist that activates the GLP-1, GIP and glucagon receptors from a single peptide backbone. It is studied in metabolic research for its effects on body weight, energy expenditure and glycaemic control, and has progressed through Eli Lilly's Phase 3 TRIUMPH clinical program.

What is retatrutide also known as?
Retatrutide's development code name is LY3437943, sometimes written LY-3437943. It is also referred to as reta or the reta peptide in research shorthand.

What's in the Box of 10?
This box contains ten individually sealed 10mg vials of lyophilised retatrutide, 100mg of peptide in total, all drawn from the same COA-verified production batch. Each vial is reconstituted and used separately; the box simply packages ten of the standard 10mg vial into one order.

How much do I save buying the Box of 10 instead of single vials?
The box is $1,099.99, about $109.99 per vial, compared with $159.99 per vial when bought individually, a saving of roughly 31 percent per vial. It's the most cost-effective way to secure a 10mg supply if your protocol is already running on that dose.

Can I buy retatrutide at Chemist Warehouse or a pharmacy in Australia?
No. Retatrutide is not a registered medicine in Australia and is not listed on the Australian Register of Therapeutic Goods, so it is not stocked by Chemist Warehouse, Priceline or other retail pharmacies. Omega Peptides Australia supplies retatrutide only as a research-grade lyophilised compound for in-vitro laboratory work.

Can Australian compounding pharmacies supply retatrutide?
Compounding pharmacies in Australia may only prepare a medicine for an individual patient on a prescription from a registered practitioner, and the TGA has warned about the uncertainties of compounded unapproved peptide products. Retatrutide is not an approved ingredient. Research suppliers such as Omega Peptides Australia supply the lyophilised research compound for laboratory use, which is a separate pathway from pharmacy compounding.

How does retatrutide work?
Retatrutide activates three receptors from one peptide backbone: GLP-1R and GIPR, which together drive glucose-dependent insulin secretion and appetite suppression, and the glucagon receptor (GCGR), which increases hepatic fatty acid oxidation and energy expenditure. A fatty-acid side chain allows the peptide to bind reversibly to albumin, extending its half-life to support once-weekly dosing in research protocols.

What does the research show about retatrutide?
Retatrutide has been evaluated in Eli Lilly's Phase 3 TRIUMPH program, including the TRIUMPH-1 and TRIUMPH-3 trials, which reached primary completion in April 2026. Reported trial data has shown weight reductions in the order of 15 to 24 percent over 48 to 72 weeks, with some extended dosing arms reporting up to roughly 28 percent at 80 weeks. The most commonly reported adverse effects are gastrointestinal, including nausea and diarrhoea, with a comparatively low reported risk of hypoglycaemia.

How do you reconstitute the vials in this box?
Reconstitute one vial at a time as you need it. Add bacteriostatic water slowly down the inside wall of the vial so it runs onto the powder gently, then swirl gently until the solution is clear. Do not shake the vial. The reconstitution calculator gives the volume needed for a chosen concentration. Once reconstituted, keep that vial refrigerated at 2–8°C and use within 28 days; the remaining unopened vials stay lyophilised until needed.

How should this box be stored?
Store all sealed lyophilised vials at 2–8°C for short-term use or at −20°C for long-term storage, protected from light and moisture, and avoid repeated freeze-thaw cycles. Reconstitute vials individually as required; each reconstituted vial should be refrigerated at 2–8°C and used within 28 days.

Where can I buy a box of retatrutide in Australia?
Omega Peptides Australia holds retatrutide in domestic stock and dispatches orders placed before 12pm on the same business day, including this Box of 10 x 10mg. Every batch is COA-verified by an independent laboratory and the certificates are published online. Order this box here, or see our main Retatrutide listing for single vials in 5mg, 10mg, 20mg, 30mg and 60mg.

What does this Box of 10 cost in Australia?
This box is $1,099.99 for ten 10mg vials, about $109.99 per vial, compared with $159.99 for a single 10mg vial. Bacteriostatic water for reconstitution is sold separately, and given the number of vials in this box, most researchers order two or more.

How do I get this box online in Australia?
Add this box to your cart and complete checkout. Orders are shipped with tracked domestic delivery in discreet, unbranded packaging. Orders placed before 12pm are dispatched the same business day from within Australia, and a tracking number is emailed once the parcel is lodged with the carrier.

Is retatrutide legal in Australia?
Omega Peptides Australia supplies retatrutide strictly for lawful in-vitro laboratory research. It is not approved by the TGA for human or veterinary use and is not sold as a medicine or supplement. Purchasers are responsible for ensuring their intended use complies with all applicable laws.

How does retatrutide differ from tirzepatide?
Tirzepatide is a dual agonist of the GLP-1 and GIP receptors. Retatrutide activates those same two receptors plus a third, the glucagon receptor, which adds a hepatic energy-expenditure mechanism not present in tirzepatide. Researchers often compare the two to separate the contribution of glucagon receptor signalling from GLP-1/GIP dual agonism. See our full Retatrutide vs Tirzepatide comparison for more detail.

⚠ For in-vitro research and laboratory use only. Not for human or veterinary use.